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Ⅰ．Introduction
 Human parechovirus （HPeV） is an important 
cause of fever in young infants, who characteristically 
present with fever and irritability and occasionally 
also present a diffuse rash［1］. The severe form of 
the disease can lead to meningoencephalitis, seizure, 
sepsis-like presentations including septic shock as 
well as less common presentations including signs 
of surgical abdomen［2-7］. There are no effective 
antiviral therapies. Treatment is primarily supportive 
and includes management of complications. Some 
infants with a severe HPeV infection may show adverse 
neurodevelopment, and follow-up by a pediatrician is 
recommended［8-10］. Hyper-cytokinemia is suspected 
as the biochemical background of HPeV infections
［11,12］. We experienced several infantile cases of 
HPeV infection and assessed their interleukin-6 levels. 
Ⅱ．Case
 A 2-month-old boy visited a clinic due to high fever 
and poor feeding. He was previously healthy with no 
family history of infection. Sepsis was suspected, and he 
was transferred from the clinic to a local hospital. After 
multiple cultures were done, antibiotic treatment was 
begun. On day 2, during a brain MRI under sedation, the 
patient presented apnea leading to respiratory difficulty 
with foamy sputum. The MRI was discontinued, and the 
patient was intubated immediately. A chest XP and CAT 
scan revealed decreased permeability of the bilateral 
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Abstract
Human parechovirus （HPeV）, a potentially severe viral infection in infants and one of the 
chief causes of fever in young infants, typically presents fever, irritability, and rash, thus accounting 
for the patients’ being described as “hot, red, angry babies”. Treatment is primarily supportive and 
includes management of complications. Some infants with a severe HPeV infection may suffer adverse 
neurodevelopment, and follow-ups by a pediatrician are recommended. We experienced an infantile 
case of HPeV infection requiring critical care in which the interleukin-6 levels was not elevated. 
The immune response in HPeV infections is not fully understood and requires further study for 
clarification.
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lungs （Fig. 1 （a）, （b））. An echocardiogram disclosed 
an ejection fraction of 10%, and he was referred to our 
hospital for further treatment.
 On admission to the pediatric ICU his vital signs 
showed tachycardia （HR over 180’s/minute） and 
hypotension （systolic BP under 60’s mmHg） while 
the blood gas analysis showed a high lactate level 
（over 5 mmol/dL）. His clinical condition put him at 
risk of cardiogenic shock. Inotrope and lucinotrope 
（epinephrine and milrinon） were started. The spectrum 
of the antibiotics was broadened, and a high dose of 
corticosteroid for sepsis was administered. During the 
course of his ICU stay, he required intermittent use of 
high frequency oscillatory ventilation （HFOV） but was 
extubated on ICU day 9 and discharged from the ICU 
on day 10 （Fig. 2）.
 The serum interleukin-6 （IL-6） level was measured 
in this case （ICU day 1） by RAY-FASTTM（TORAY 
Co., Ltd）, however, IL-6 was not elevated.
Ⅲ．Discussion
 HPeV is increasingly being recognized as a 
potentially severe viral infection in infants. HPeV 
belongs to the family Picornaviridae and is currently 
divided into 19  genotypes［13］.  HPeV-1  is the 
most prevalent genotype and commonly causes 
gastrointestinal and respiratory disease. HPeV-3 is 
clinically the most important genotype due to its 
association with severe disease states in younger infants, 
which may partly be explained by its distinct virological 
properties［14-16］. In young infants, the typical clinical 
presentation includes fever, irritability, and rash, which 
account for the description of the patients as “hot, red, 
angry babies”［1］.
 Although HPeV infection increases the risk of 
long-term neurological sequelae, the clinical course 
is self-limiting even when ICU admission is required. 
Molecular diagnosis for early detection should be 
included in the standard assessment for sepsis-like 
illnesses and general supportive critical care［17］. Early 
diagnosis is helpful for minimizing the unnecessary use 
of broad spectrum antibiotics, predicting the clinical 
course in the ICU, and preparing long-term, post-
discharge neurological follow up.
 Several studies suggested that the serum and/or 
cerebrospinal fluid （CSF） cytokine levels change in 
Fig. 1　Chest XP and CAT scan of this case
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Fig. 2　Clinical course of this case in the pediatric ICU
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HPeV infections. While Fortuna reported that CSF IL-6 
and IL-8 were not elevated in HPeV cases［11］, Yokota 
demonstrated that serum IL-6, IL-10, and interferon 
gamma were elevated in severe cases［12］. Fortuna 
measured cytokines levels comparing HPeV and 
enterovirus （EV）, and he concluded that the immune 
response to HPeV infection differs from that of EV. 
Yokota measured cytokine levels in HPeV type 3 only. 
HPeV was known to have several genotypes［17］, and 
type 3 is also known to be severe and show sepsis like 
clinical picture［5,6］. Our case showed no elevation 
of IL-6 on ICU day 1, however, we didn’t analyze 
genotypes and this is one of our report limitations. 
The immune response in HPeV infections is not yet 
fully understood, and further research is needed for 
clarification.
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